As research into hemp-derived cannabinoids continues to expand, scientists are learning that cannabinoids like CBD and CBG may affect the body in very different ways. In the study “Cannabigerol and cannabidiol differ in their ability to affect the AhR/CYP1A pathway in vitro,” researchers explored how these two cannabinoids interact with biological pathways connected to detoxification and cellular response systems. The AhR/CYP1A pathway helps the body process certain compounds and plays a role in inflammation, oxidative stress, and cellular balance. (Bioactive Informatics)

The findings showed that CBG and CBD influenced this pathway differently, reinforcing the growing understanding that cannabinoids each have their own unique properties and mechanisms of action. Researchers observed that CBD demonstrated stronger activity within parts of the pathway, while CBG responded differently at the cellular level. This may help explain why some users report different wellness experiences when using products formulated with specific cannabinoid profiles instead of CBD alone. (Bioactive Informatics)

Studies like this continue to support the importance of cannabinoid diversity within hemp products. As scientists further explore how cannabinoids interact with receptors, enzymes, and signaling pathways throughout the body, emerging research continues to highlight the potential value of broad-spectrum and multi-cannabinoid formulations for supporting overall wellness and balance.

Source

Vrba J, Havlasek J, Dostalova K, et al. Cannabigerol and cannabidiol differ in their ability to affect the AhR/CYP1A pathway in vitro. Food and Chemical Toxicology. Published May 14, 2026. (Bioactive Informatics) https://pubmed.ncbi.nlm.nih.gov/42134486/?utm_source=chatgpt.com